HC Wainwright Forecasts Reduced Earnings for Kodiak Sciences

Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - Stock analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for Kodiak Sciences in a research report issued on Monday, May 19th. HC Wainwright analyst M. Caufield now expects that the company will post earnings of ($1.09) per share for the quarter, down from their previous estimate of ($0.99). HC Wainwright currently has a "Neutral" rating and a $3.00 target price on the stock. The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences' Q3 2025 earnings at ($1.09) EPS, Q4 2025 earnings at ($1.09) EPS, FY2025 earnings at ($4.36) EPS, FY2026 earnings at ($4.75) EPS, FY2027 earnings at ($4.20) EPS, FY2028 earnings at ($2.97) EPS and FY2029 earnings at ($1.56) EPS.

Kodiak Sciences Stock Down 3.1%

Shares of NASDAQ KOD traded down $0.11 during mid-day trading on Wednesday, reaching $3.44. 220,235 shares of the company were exchanged, compared to its average volume of 350,031. The company's 50 day moving average price is $3.30 and its 200 day moving average price is $5.48. Kodiak Sciences has a 52 week low of $1.92 and a 52 week high of $11.60. The stock has a market capitalization of $181.51 million, a PE ratio of -0.94 and a beta of 2.42.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($1.09) EPS for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.20).

Hedge Funds Weigh In On Kodiak Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. increased its holdings in shares of Kodiak Sciences by 1,501.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company's stock worth $32,000 after purchasing an additional 2,988 shares in the last quarter. American Century Companies Inc. increased its holdings in Kodiak Sciences by 6.2% in the 4th quarter. American Century Companies Inc. now owns 59,967 shares of the company's stock worth $597,000 after buying an additional 3,515 shares in the last quarter. US Bancorp DE purchased a new position in Kodiak Sciences in the 4th quarter worth about $40,000. Bank of New York Mellon Corp lifted its stake in Kodiak Sciences by 5.3% during the 4th quarter. Bank of New York Mellon Corp now owns 98,102 shares of the company's stock valued at $976,000 after acquiring an additional 4,927 shares during the period. Finally, Deutsche Bank AG boosted its holdings in shares of Kodiak Sciences by 8.9% during the 1st quarter. Deutsche Bank AG now owns 73,564 shares of the company's stock valued at $207,000 after acquiring an additional 6,018 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.